Combigene (Sweden) Insiders
| COMBI Stock | SEK 2.60 0.06 2.26% |
Combigene employs about 11 people. The company is managed by 6 executives with a total tenure of roughly 26 years, averaging almost 4.0 years of service per executive, having 1.83 employees per reported executive. Breaking down Combigene's management performance can provide insight into the firm performance.
| Jan Nilsson Insider Chief Officer |
| Louise Aspenberg Insider Chief Officer |
Combigene |
Combigene Management Team Effectiveness
The company has return on total asset (ROA) of 0.2071 % which means that it generated a profit of $0.2071 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4774 %, meaning that it generated $0.4774 on every $100 dollars invested by stockholders. Combigene's management efficiency ratios could be used to measure how well Combigene manages its routine affairs as well as how well it operates its assets and liabilities.Combigene Workforce Comparison
Combigene AB is number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 157. Combigene holds roughly 11.0 in number of employees claiming about 7% of stocks in Biotechnology industry.
The company has Profit Margin (PM) of 0.59 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.42 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.42. Combigene AB Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Combigene AB Price Series Summation is a cross summation of Combigene price series and its benchmark/peer.
Combigene Notable Stakeholders
A Combigene stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Combigene often face trade-offs trying to please all of them. Combigene's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Combigene's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jan Nilsson | Chief Officer | Profile | |
| Louise Aspenberg | Chief Officer | Profile | |
| Associate Woldbye | Scientific Founder | Profile | |
| Pr Kokaia | Scientific Founder | Profile | |
| Karin Agerman | Chief Officer | Profile | |
| Peter Ekolind | Chief Officer | Profile |
About Combigene Management Performance
The success or failure of an entity such as Combigene AB often depends on how effective the management is. Combigene management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Combigene management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Combigene management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
CombiGene AB engages in the development and commercialization of gene therapy for the treatment of neurological and psychiatric disorders. CombiGene AB was founded in 1999 and is headquartered in Lund, Sweden. Combigene operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 7 people.
Please note, the imprecision that can be found in Combigene's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Combigene AB. Check Combigene's Beneish M Score to see the likelihood of Combigene's management manipulating its earnings.
Combigene Workforce Analysis
Traditionally, organizations such as Combigene use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Combigene within its industry.Combigene Manpower Efficiency
Return on Combigene Manpower
| Revenue Per Employee | 7.6M | |
| Revenue Per Executive | 14M | |
| Net Income Per Employee | 1.9M | |
| Net Income Per Executive | 3.5M | |
| Working Capital Per Employee | 1000K | |
| Working Capital Per Executive | 1.8M |
Additional Tools for Combigene Stock Analysis
When running Combigene's price analysis, check to measure Combigene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Combigene is operating at the current time. Most of Combigene's value examination focuses on studying past and present price action to predict the probability of Combigene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Combigene's price. Additionally, you may evaluate how the addition of Combigene to your portfolios can decrease your overall portfolio volatility.